The authors wish to make the following corrections to this paper [1]:
The 33 references in Table 1 were incorrectly linked to the bibliography in the original manuscript due to a problem with the reference manager software. The original Table 1 is listed below:
Table 1.
MRT Parameters Used in Cancer Models.
| Animal | Cancer Type | Number of Arrays | Microbeam | Peak-Dose (Gy) | Valley-Dose (Gy) | Evaluated Criteria | |
|---|---|---|---|---|---|---|---|
| Width (µm) | Spacing (µm) | ||||||
| Rat [1] | Gliosarcoma (9L) | 1 & 2 | 50 | 200 | 400 entrance dose; 350 @1cm depth |
12.5 @1cm depth | Animal survival, tumour growth, tumour vasculature, and cell proliferation |
| Rat [2] | Gliosarcoma (9L) | 2 | 50 | 200 | 480 entrance dose; 418 @1cm depth |
18.6 @1cm depth | Animal survival, cell cycle, and DNA distribution patterns |
| Rat [3] | Gliosarcoma (9L) | 2 | 50 | 200 | 400 entrance dose; 350 @1cm depth |
12.5 @1cm depth | Tumour vasculature and tumour oxygenation |
| Rat [4] | Gliosarcoma (9L) | 1 | 50 | 200 | 400 dose @tumour (i.e., @7mm depth) |
18 dose @tumour (i.e., @7mm depth) | Animal survival and Transcriptomics |
| Rat [5] | Gliosarcoma (9L) | 1 | 50 | 200 | 400 dose @tumour (i.e., @7mm depth) |
8 dose @tumour (i.e., @7mm depth) | Tumour growth, transcriptomics, and histopathology |
| Rat [6] | Gliosarcoma (9L) | 1 | 50 | 200 | 400 dose @tumour (i.e., @7mm depth) |
17.4 dose @tumour (i.e., @7mm depth) | Animal survival, tumour growth, cell proliferation, and gene expression |
| 200 dose @tumour (i.e., @7mm depth) | 8.7 dose @tumour (i.e., @7mm depth) | ||||||
| Rat [7] | Glioma (F98) | 2 | 50 | 200 | 241.4 entrance dose | 10.5 @9mm depth | Tumour vasculature and tumour oxygenation |
| Mouse [8] | Mammary (EMT6.5/67NR) | 1 | 25 | 200 | 560 entrance dose | 8.5 @centre of brain | Animal survival, DNA damage, cell proliferation, and apoptosis |
| 800 entrance dose | 12 @centre of brain | ||||||
| 2 | 280 entrance dose | 8.5 @centre of brain | |||||
| 560 entrance dose | 17 @centre of brain | ||||||
| Rat [9] | Gliosarcoma (9L) | 1 | 27 | 50 | 150 entrance dose; 108 @centre of brain |
20 @centre of brain | Animal survival and histopathology |
| 250 entrance dose; 179 @centre of brain |
34 @centre of brain | ||||||
| 300 entrance dose; 215 @centre of brain |
40 @centre of brain | ||||||
| 75 | 250 entrance dose; 179 @centre of brain |
17 @centre of brain | |||||
| 300 entrance dose; 215 @centre of brain |
20 @centre of brain | ||||||
| 500 entrance dose; 359 @centre of brain |
33 @centre of brain | ||||||
| 100 | 500 entrance dose; 359 @centre of brain |
19 @centre of brain | |||||
| Mouse [10] | Mammary (EMT6.5) | 1 | 90 | 300 | 800 dose @tumour | 16 dose @tumour | Tumour ablation |
| 890 dose @tumour | 18 dose @tumour | ||||||
| 970 dose @tumour | 19 dose @tumour | ||||||
| 1740 dose @tumour | 35 dose @tumour | ||||||
| 1820 dose @tumour | 36 dose @tumour | ||||||
| 1900 dose @tumour | 38 dose @tumour | ||||||
| 2 | 90 | 300 | 410 dose @tumour | 16 dose @tumour | |||
| 520 dose @tumour | 21 dose @tumour | ||||||
| 650 dose @tumour | 26 dose @tumour | ||||||
| Rat [11] | Glioma (C6) | 1 | 25 | 200 | 17.5, 35, 70, 350 entrance dose | 0.51, 1.03, 2, 10.3 | Bystander effects in-vivo by clonogenic cell survival |
| Rat [12] | Glioma (C6) | 1 | 25 | 200 | 35, 70, 350 entrance dose | NR | DNA damage |
| Rat [13] | Glioma (F98) | 1 | 25 | 200 | 20, 200 entrance dose | NR | Bystander effects in-vivo by clonogenic cell survival and cellular calcium fluxes |
| Mouse nude [14] | Glioma (F98) | 50 | 400 | 22, 110 entrance dose | 0.5, 2.5 | Bystander effects in-vivo by clonogenic cell survival and cellular calcium fluxes | |
| Mouse [15] | Mammary (4T1) | 1 | 50 | 200 | 150 @5 mm depth | 7.5 in a 10 mm solid water phantom |
Tumour growth, tumour vasculature, and tumour hypoxia |
| Mouse [16] | Mammary (EMT6.5) | 1 | 25 | 200 | 112, 560 | NR | Immune response by gene expression and histopathology |
| Rat [17] | Gliosarcoma (9L) | 1 | 50 | 200 | 400 entrance dose | NR | Tumour vasculature, and tumour hypoxia |
| Rat [18] | Gliosarcoma (9L) | 1 | 25 | 100 | 625 entrance dose | NR | Animal survival, tumour growth, and histopathology |
| Mouse [19] | Squamous cell carcinoma (SCCVII) | 1 | 35 | 200 | 442, 625, 884 entrance dose | NR | Animal survival, tumour growth, and tumour ablation |
| 70 | 200 | 442 entrance dose | |||||
| Rat [20] | Glioma (C6) | 2 | 25 | 200 | 350 entrance dose | NR | Optic nerve damage by histopathology |
| Mouse [21] | Melanoma (B16F10) | 1 | 50 | 200 | 407.6 dose @tumour | 6.2 dose @tumour | Tumour growth, tumour vasculature, cell proliferation, cell senescence, and immune response |
| Rat [22] | Gliosarcoma (9L) | 1 | 25 | 200 | 625 entrance dose | 12.1 dose @tumour | Animal survival, tumour growth, and histopathology |
| 100 | 625 entrance dose | 36 dose @tumour | |||||
| Rat [23] | Gliosarcoma (9L) | 1 | 25 | 200 | 625 entrance dose | NR | Animal survival, tumour growth, and histopathology |
| Mouse [24] | Mammary (EMT6.5) | 1 | 25 | 200 | 560 entrance dose | 11 | Biochemical changes by synchrotron Fourier-transform infrared microspectroscopy |
| Rat [25] | Glioma (C6, F98) | 2 | 25 | 211 | 350 entrance dose | NR | Animal survival and object recognition |
| Rat [26] | Glioma (F98) | 2 | 28 | 400 | 350 | 18 dose @ tumour | Animal survival and cognitive dysfunction |
| Mouse nude [27] | Gliosarcoma (9L) | 1 | 25 | 211 | 500 entrance dose | 24 (cross-fired) | Animal survival, tumour growth, and tumour vasculature |
| Rat [28] | Gliosarcoma (9L) | 2 | 25 | 211 | 860 entrance dose | 18 @1cm depth | Animal survival and histopathology |
| 50 | 480 entrance dose | ||||||
| 75 | 320 entrance dose | ||||||
| Rat [29] | Gliosarcoma (9L) | 3 | 50 | 211 | 400, 360 (+24h), 400 (+48h) entrance dose | 15 | Animal survival and histopathology |
| Rat [30] | Gliosarcoma (9L) | 1 | 27 | 211 | 625 entrance dose | NR | Animal survival, histopathology, and immune response |
| Mouse [31] | Mammary (EMT6.5) | 1 | 25 | 200 | 560 | 11 | Transcriptomics |
| Mouse nude [32] | Glioma (U251) | 1 | 100 | 500 | 124 | 4.8 | Tumour growth, histopathology, and apoptosis |
| 2 | 20 | 100 | 111 | 8.2 | |||
| 100 | 500 | 124 | 9.6 | ||||
| Mouse [33] | Mammary (EMT6.5) | 1 | 25 | 200 | 112, 560 | NR | Immune response |
NR: Not-Reported.
And should be replaced with the following version:
Table 1.
MRT parameters used in cancer models.
| Animal | Cancer Type | Number of Arrays | Microbeam | Peak Dose (Gy) | Valley Dose (Gy) | Evaluated Criteria | |
|---|---|---|---|---|---|---|---|
| Width (µm) | Spacing (µm) | ||||||
| Rat [32] | Gliosarcoma (9L) | 1 and 2 | 50 | 200 | 400 entrance dose; 350 @ 1 cm depth |
12.5 @ 1 cm depth | Animal survival, tumour growth, tumour vasculature, and cell proliferation |
| Rat [37] | Gliosarcoma (9L) | 2 | 50 | 200 | 480 entrance dose; 418 @ 1 cm depth |
18.6 @ 1 cm depth | Animal survival, cell cycle, and DNA distribution patterns |
| Rat [33] | Gliosarcoma (9L) | 2 | 50 | 200 | 400 entrance dose; 350 @ 1 cm depth |
12.5 @ 1 cm depth |
Tumour vasculature and tumour oxygenation |
| Rat [29] | Gliosarcoma (9L) | 1 | 50 | 200 | 400 dose @ tumour (i.e., @ 7 mm depth) |
18 dose @ tumour (i.e., @ 7 mm depth) | Animal survival and transcriptomics |
| Rat [30] | Gliosarcoma (9L) | 1 | 50 | 200 | 400 dose @ tumour (i.e., @ 7 mm depth) |
8 dose @ tumour (i.e., @ 7 mm depth) | Tumour growth, transcriptomics, and histopathology |
| Rat [31] | Gliosarcoma (9L) | 1 | 50 | 200 | 400 dose @ tumour (i.e., @ 7 mm depth) |
17.4 dose @ tumour (i.e., @ 7 mm depth) | Animal survival, tumour growth, cell proliferation, and gene expression |
| 200 dose @ tumour (i.e., @ 7 mm depth) | 8.7 dose @ tumour (i.e., @ 7 mm depth) | ||||||
| Rat [42] | Glioma (F98) | 2 | 50 | 200 | 241.4 entrance dose | 10.5 @ 9 mm depth | Tumour vasculature and tumour oxygenation |
| Mouse [50] | Mammary (EMT6.5/67NR) | 1 | 25 | 200 | 560 entrance dose | 8.5 @ centre of brain | Animal survival, DNA damage, cell proliferation, and apoptosis |
| 800 entrance dose | 12 @ centre of brain | ||||||
| 2 | 280 entrance dose | 8.5 @ centre of brain | |||||
| 560 entrance dose | 17 @ centre of brain | ||||||
| Rat [15] | Gliosarcoma (9L) | 1 | 27 | 50 | 150 entrance dose; 108 @ centre of brain |
20 @ centre of brain | Animal survival and histopathology |
| 250 entrance dose; 179 @ centre of brain |
34 @ centre of brain | ||||||
| 300 entrance dose; 215 @ centre of brain |
40 @ centre of brain | ||||||
| 75 | 250 entrance dose; 179 @ centre of brain |
17 @ centre of brain | |||||
| 300 entrance dose; 215 @ centre of brain |
20 @ centre of brain | ||||||
| 500 entrance dose; 359 @ centre of brain |
33 @ centre of brain | ||||||
| 100 | 500 entrance dose; 359 @ centre of brain |
19 @ centre of brain | |||||
| Mouse [49] | Mammary (EMT6.5) | 1 | 90 | 300 | 800 dose @ tumour | 16 dose @ tumour | Tumour ablation |
| 890 dose @ tumour | 18 dose @ tumour | ||||||
| 970 dose @ tumour | 19 dose @ tumour | ||||||
| 1740 dose @ tumour | 35 dose @ tumour | ||||||
| 1820 dose @ tumour | 36 dose @ tumour | ||||||
| 1900 dose @ tumour | 38 dose @ tumour | ||||||
| 2 | 90 | 300 | 410 dose @ tumour | 16 dose @ tumour | |||
| 520 dose @ tumour | 21 dose @ tumour | ||||||
| 650 dose @ tumour | 26 dose @ tumour | ||||||
| Rat [19] | Glioma (C6) | 1 | 25 | 200 | 17.5, 35, 70, 350 entrance dose | 0.51, 1.03, 2, 10.3 | Bystander effects in vivo by clonogenic cell survival |
| Rat [44] | Glioma (C6) | 1 | 25 | 200 | 35, 70, 350 entrance dose | NR | DNA damage |
| Rat [43] | Glioma (F98) | 1 | 25 | 200 | 20, 200 entrance dose | NR | Bystander effects in vivo by clonogenic cell survival and cellular calcium fluxes |
| Mouse nude [47] | Glioma (F98) | 50 | 400 | 22, 110 entrance dose | 0.5, 2.5 | Bystander effects in vivo by clonogenic cell survival and cellular calcium fluxes | |
| Mouse [55] | Mammary (4T1) | 1 | 50 | 200 | 150 @ 5 mm depth | 7.5 in a 10-mm solid water phantom |
Tumour growth, tumour vasculature, and tumour hypoxia |
| Mouse [52] | Mammary (EMT6.5) | 1 | 25 | 200 | 112, 560 | NR | Immune response by gene expression and histopathology |
| Rat [38] | Gliosarcoma (9L) | 1 | 50 | 200 | 400 entrance dose | NR | Tumour vasculature, and tumour hypoxia |
| Rat [25] | Gliosarcoma (9L) | 1 | 25 | 100 | 625 entrance dose | NR | Animal survival, tumour growth, and histopathology |
| Mouse [56] | Squamous cell carcinoma (SCCVII) | 1 | 35 | 200 | 442, 625, 884 entrance dose | NR | Animal survival, tumour growth, and tumour ablation |
| 70 | 200 | 442 entrance dose | |||||
| Rat [45] | Glioma (C6) | 2 | 25 | 200 | 350 entrance dose | NR | Optic nerve damage by histopathology |
| Mouse [7] | Melanoma (B16F10) | 1 | 50 | 200 | 407.6 dose @ tumour | 6.2 dose @ tumour | Tumour growth, tumour vasculature, cell proliferation, cell senescence, and immune response |
| Rat [20] | Gliosarcoma (9L) | 1 | 25 | 200 | 625 entrance dose | 12.1 dose @ tumour | Animal survival, tumour growth, and histopathology |
| 100 | 625 entrance dose | 36 dose @ tumour | |||||
| Rat [36] | Gliosarcoma (9L) | 1 | 25 | 200 | 625 entrance dose | NR | Animal survival, tumour growth, and histopathology |
| Mouse [54] | Mammary (EMT6.5) | 1 | 25 | 200 | 560 entrance dose | 11 | Biochemical changes by synchrotron Fourier-transform infrared microspectroscopy |
| Rat [40] | Glioma (C6, F98) | 2 | 25 | 211 | 350 entrance dose | NR | Animal survival and object recognition |
| Rat [41] | Glioma (F98) | 2 | 28 | 400 | 350 | 18 dose @ tumour | Animal survival and cognitive dysfunction |
| Mouse nude [46] | Gliosarcoma (9L) | 1 | 25 | 211 | 500 entrance dose | 24 (cross-fired) | Animal survival, tumour growth, and tumour vasculature |
| Rat [34] | Gliosarcoma (9L) | 2 | 25 | 211 | 860 entrance dose | 18 @ 1 cm depth | Animal survival and histopathology |
| 50 | 480 entrance dose | ||||||
| 75 | 320 entrance dose | ||||||
| Rat [35] | Gliosarcoma (9L) | 3 | 50 | 211 | 400, 360 (+24 h), 400 (+48 h) entrance dose | 15 | Animal survival and histopathology |
| Rat [39] | Gliosarcoma (9L) | 1 | 27 | 211 | 625 entrance dose | NR | Animal survival, histopathology, and immune response |
| Mouse [51] | Mammary (EMT6.5) | 1 | 25 | 200 | 560 | 11 | Transcriptomics |
| Mouse nude [48] | Glioma (U251) | 1 | 100 | 500 | 124 | 4.8 | Tumour growth, histopathology, and apoptosis |
| 2 | 20 | 100 | 111 | 8.2 | |||
| 100 | 500 | 124 | 9.6 | ||||
| Mouse [53] | Mammary (EMT6.5) | 1 | 25 | 200 | 112, 560 | NR | Immune response |
NR: not reported.
The authors would like to apologize for any inconvenience caused to the readers by these changes. The original article has been updated.
Footnotes
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Fernandez-Palomo C., Fazzari J., Trappetti V., Smyth L., Janka H., Laissue J., Djonov V. Animal Models in Microbeam Radiation Therapy: A Scoping Review. Cancers. 2020;12:527. doi: 10.3390/cancers12030527. [DOI] [PMC free article] [PubMed] [Google Scholar]